Skip to content
OpenCapital
Get started

Sanara MedTech Inc. SMTI Debt Maturity - 2027

Debt Maturity - 2027 at other companies

IAR
Integra LifeSciencesIART
$634.53M0.0%
Bioventus logo
BioventusBVS
$15M—
CONMED logo
CONMEDCNMD
$0—
Solventum logo
SolventumSOLV
——

Other financials

Income statement

See full
Revenue$27.8M+18.6%
Gross profit$25.9M+19.8%
Operating income$2.6M+221%
Net income$459.0K+113%
EPS (diluted)$0.05+112%

Balance sheet

See full
Cash & equivalents$13.6M-34.3%
Total debt$48.4M+8.2%
Total equity$7.0M-80.8%
Total assets$69.3M-28.1%

Cash flow

See full
Operating cash flow-$2.5M-23.3%
CapEx$43.8K-97.5%
Free cash flow-$2.5M+32.6%

Valuation

See full
Market cap$216.18M-9.7%
Enterprise value$250.95M-6.5%
P/S2×-0.5×

Profitability

See full
Gross margin92.9%+1.8pp
Operating margin6.1%+5.1pp
Net margin-31.2%-93.4pp
FCF margin-9.8%-3.5pp

Returns & leverage

See full
Return on equity-153.7%-199pp
Debt / equity6.9×+5.7×
Current ratio2.3×-0.5×

Where this comes from

Reported directly by Sanara MedTech Inc. in its filing.

Tagged under the XBRL concept us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree.

The official record: Sanara MedTech Inc.’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about Sanara MedTech Inc.'s debt maturity - 2027.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Sanara MedTech Inc.'s debt maturity - 2027?
Sanara MedTech Inc. (SMTI) reported debt maturity - 2027 of $47.11M in Q1 2026.
How has Sanara MedTech Inc.'s debt maturity - 2027 changed year-over-year?
Sanara MedTech Inc.'s debt maturity - 2027 increased by 5.8% year-over-year, from $44.53M to $47.11M.
What is the long-term trend for Sanara MedTech Inc.'s debt maturity - 2027?
Over 2 years (2023 to 2025), Sanara MedTech Inc.'s debt maturity - 2027 has grown at a 390.6% compound annual growth rate (CAGR), from $1.95M to $46.93M.
What does debt maturity - 2027 mean?
The specific principal amount of debt obligations scheduled to mature in the year 2027. This metric is essential for assessing the company's liquidity risk and refinancing requirements in a specific future period. It helps investors understand the timing of potential cash outflows related to debt repayment.